Citations

Showing 10 of 108119 citations.

Novel Genetic Risk Variants Can Predict Anti-TNF Agent Response in Patients With Inflammatory Bowel Disease
Wang, Ming‐Hsi , Friton, Jessica, Raffals, Laura E. , Leighton, Jonathan A. , Pasha, Shabana F., Picco, Michael F., Monroe, Kelly, Nix, Billy D., Newberry, Rodney D. , Faubion, William A. , Friton, Jessica J, Cushing, Kelly C. , Newberry, Rodney D

Mayo Clinic

Journal of Crohn's and Colitis | January 21, 2019 | Volume: 13 | Issue: 8 | Pages: 1036-1043

10.1093/ecco-jcc/jjz017 | PMID 30689765 Get It

AbstractBackgroundIt is important to identify patients with inflammatory bowel disease [IBD] refractory to anti-tumour necrosis factor [TNF] therapy, to avoid potential adverse effects and to adopt different treatment strategies. We aimed to identify and validate clinical and genetic factors to predict anti-TNF response in patients with IBD.Materials and MethodsMayo Clinic and Washington University IBD genetic association study cohorts were used as discovery and replicate datasets, respectively. Clinical factors included sex, age at diagnosis, disease duration and phenotype, disease location, bowel resection, tobacco use, family history of IBD, extraintestinal manifestations, and response to anti-TNF therapy.ResultsOf 474 patients with IBD treated with anti-TNF therapy, 41 [8.7%] were refractory to therapy and 433 [91.3%] had response. Multivariate analysis showed history of immunomodulator use (odds ratio 10.2, p = 8.73E-4) and bowel resection (odds ratio 3.24, p = 4.38E-4) were associated with refractory response to anti-TNF agents. Among genetic loci, two [rs116724455 in TNFSF4/18, rs2228416 in PLIN2] were successfully replicated and another four [rs762787, rs9572250, rs144256942, rs523781] with suggestive evidence were found. An exploratory risk model predictability [area under the curve] increased from 0.72 [clinical predictors] to 0.89 after adding genetic predictors. Through identified clinical and genetic predictors, we constructed a preliminary anti-TNF refractory score to differentiate anti-TNF non-responders (mean [standard deviation] score, 5.49 [0.99]) from responders (2.65 [0.39]; p = 4.33E-23).ConclusionsNovel and validated genetic loci, including variants in TNFSF, were found associated with anti-TNF response in patients with IBD. Future validation of the exploratory risk model in a large prospective cohort is warranted.
Cerebrovascular reactivity after cessation of menopausal hormone treatment
Barnes, Jill N. , Harvey, Ronée E. , Eisenmann, Nicole A., Miller, Kathleen B. , Johnson, M. C., Kruse, Sarah, Lahr, Brian D. , Miller, Virginia M. , Barnes, J N , Harvey, Ronée E , Joyner, Michael J.

Mayo Clinic

Climacteric | January 21, 2019 | Volume: 22 | Issue: 2 | Pages: 182-189

10.1080/13697137.2018.1538340 | PMID 30661405 Get It

Familial chronic megacolon presenting in childhood or adulthood: Seeking the presumed gene association
Camilleri, Michael , Wieben, Eric D. , Eckert, Deborah J., Carlson, Paula, O’Dwyer, Ralph Hurley , Gibbons, Denys , Klee, Eric W. , Wieben, Eric, Eckert, Deborah, Hurley O'Dwyer, Ralph, Acosta, Andrés

Mayo Clinic

Neurogastroenterology & Motility | January 21, 2019 | Volume: 31 | Issue: 4 | Pages: No page available

10.1111/nmo.13550 | PMID 30663199 Get It

AbstractObjectiveWe identified a pedigree over five generations with 49 members, some of whom had chronic megacolon presenting in adolescence or adulthood. We aimed to assess the genetic cause of chronic megacolon through clinical and DNA studies.DesignAfter ethical approval and informed consent, family members provided answers to standard bowel disease questionnaires, radiological or surgical records, and DNA (buccal mucosal scraping). Exome DNA sequencing of colon tissue or blood DNA from seven family members with colon or duodenal dilatation, or no megacolon (n = 1) was carried out. Sanger sequencing was performed in 22 additional family members to further evaluate candidate variants. The study focused on genes of potential relevance to enteric nerve (ENS) maturation and Hirschsprung's disease or megacolon, based on the literature (GFRA1, NKX2‐1, KIF26A, TPM3, ACTG2, SCN10A, and C17orf107 [CHRNE]) and other genetic variants that co‐segregated with megacolon in the six affected family members.ResultsInformation was available in all except five members alive at time of study; among 30 members who provided DNA, six had definite megacolon, one megaduodenum, seven significant constipation without bowel dilatation, and 16 normal bowel function by questionnaire. Among genes studied, SEMA3F (g.3:50225360A>G; c1873A>G) was found in 6/6 family members with megacolon. The SEMA3F gene variant was assessed as potentially pathogenic, based on M‐CAP in silico prediction. SEMA3F function is associated with genes (KIT and PDGFRB) that impact intestinal pacemaker function.ConclusionFamilial chronic megacolon appears to be associated with SEMA3F, which is associated with genes impacting enteric nerve or pacemaker function.
Clinical effectiveness of repetitive transcranial magnetic stimulation treatment in children and adolescents with neurodevelopmental disorders: A systematic review
Masuda, Fumi , Miyazaki, Takahiro , Tarumi, Ryosuke, Ogyu, Kamiyu , Wada, Masataka , Tsugawa, Sakiko , Mimura, Masaru , Noda, Yoshihiro , Croarkin, Paul E. , Noda, Yoshihiro , Nakajima, Shinichiro

Mayo Clinic

Autism | January 21, 2019 | Volume: 23 | Issue: 7 | Pages: 1614-1629

10.1177/1362361318822502 | PMID 30663323 Get It

Neurodevelopmental disorders, including autism spectrum disorder, are common in children and adolescents, but treatment strategies remain limited. Although repetitive transcranial magnetic stimulation has been studied for neurodevelopmental disorders, there is no clear consensus on its therapeutic effects. This systematic review examined literature on repetitive transcranial magnetic stimulation for children and adolescents with neurodevelopmental disorders published up to 2018 using the PubMed database. The search identified 264 articles and 14 articles met eligibility criteria. Twelve of these studies used conventional repetitive transcranial magnetic stimulation and two studies used theta burst stimulation. No severe adverse effects were reported in these studies. In patients with autism spectrum disorder, low-frequency repetitive transcranial magnetic stimulation and intermittent theta burst stimulation applied to the dorsolateral prefrontal cortex may have therapeutic effects on social functioning and repetitive behaviors. In patients with attention deficit/hyperactivity disorder, low-frequency repetitive transcranial magnetic stimulation applied to the left dorsolateral prefrontal cortex and high-frequency repetitive transcranial magnetic stimulation applied to the right dorsolateral prefrontal cortex may target inattention, hyperactivity, and impulsivity. In patients with tic disorders, low-frequency repetitive transcranial magnetic stimulation applied to the bilateral supplementary motor area improved tic symptom severity. This systematic review suggests that repetitive transcranial magnetic stimulation may be a promising intervention for children and adolescents with neurodevelopmental disorders. The results warrant further large randomized controlled trials of repetitive transcranial magnetic stimulation in children with neurodevelopmental disorders.
Randomised clinical trial: pregabalin vs placebo for irritable bowel syndrome
Saito, Yuri A. , Almazar, Ann E., Tilkes, Katherine E., Choung, Rok Seon , Norstrand, Michael D. Van, Schleck, Cathy D. , Zinsmeister, Alan R., Talley, Nicholas J. , Van Norstrand, Michael D, Choung, Rok Seon

Mayo Clinic

Alimentary Pharmacology & Therapeutics | January 20, 2019 | Volume: 49 | Issue: 4 | Pages: 389-397

10.1111/apt.15077 | PMID 30663077 Get It

Summary Background Pregabalin is a calcium channel α2δ ligand that modifies visceral hypersensitivity in IBS patients. Clinical data for pregabalin in IBS are lacking. Aim To test the efficacy of pregabalin on gastrointestinal symptoms in IBS patients. Methods A double‐blind, placebo‐controlled trial was performed. Adults meeting IBS Rome III criteria with ≥3 pain attacks per month were randomised to pregabalin 225 mg vs placebo twice daily for 12 weeks. Questionnaires were completed weekly. The primary endpoint was average pain Bowel Symptom Scale (BSS) scores weeks 9‐12. An intention‐to‐treat analysis of covariance evaluated treatment effects on quantitative endpoints, adjusting for age and gender. Adequate relief and change in pain score were assessed using a chi‐squared test. Results Eighty‐five patients were recruited and randomised. Sample characteristics include: mean age 39.4 (SD = 14.6); 73 (86%) female; 37 (44%) IBS‐D, 29 (35%) IBS‐M, 18 (21%) IBS‐C. The pregabalin arm had lower average pain‐BSS scores weeks 9‐12 (25 vs 42, P = 0.008). Compared with placebo, the overall IBS BSS severity score was lower in the pregabalin arm (26 vs 42, P = 0.009). Differences were observed for the diarrhoea‐BSS and bloating‐BSS scores ( P = 0.049 and 0.016, respectively). No differences between groups were seen for constipation‐BSS scores. Adequate relief was not different between the two arms (46% vs 36%, P = 0.35). 63% pregabalin vs 45% placebo had a change in pain score ≥30 at week 12 from baseline ( P = 0.10). Post‐treatment IBS‐QoL scores did not differ between groups. Conclusion This trial suggests that pregabalin may be beneficial for IBS abdominal pain, bloating and diarrhoea.
Interactive reflective writing-enhanced reflection and professional identity formation in medical education – in reply to (1) Hichem Bouayed, Samiullah Dost, and Tanzeel Hussian and (2) Alexander Morgan, James Moore and Alexander Duff
Wald, Hedy S. , Anthony, David, White, Jordan , Reis, Shmuel , Esquibel, Angela Y., Esquibel, Angela

Mayo Clinic

Medical Teacher | January 20, 2019 | Volume: 41 | Issue: 2 | Pages: 236-237

10.1080/0142159x.2018.1543861 | PMID 30663478 Get It

Entorhinal cortex tau, amyloid-β, cortical thickness and memory performance in non-demented subjects
Lundt, Emily S. , Therneau, Terry M. , Vemuri, Prashanthi , Lowe, Val J. , Kantarci, Kejal , Gunter, Jeffrey L. , Senjem, Matthew L. , Graff-Radford, Jon, Albertson, Sabrina M., Petersen, Ronald C. , Jack, Clifford R. , Jack, Clifford R , Vemuri, Prashanthi , Senjem, Matthew L , Kantarci, Kejal , Knopman, David S. , Mielke, Michelle M. , Machulda, Mary M. , Boeve, Bradley F. , Jones, David T. , Graff-Radford, Jon, Schwarz, Christopher G. , Lundt, Emily S

Mayo Clinic

Brain | January 20, 2019 | Volume: 142 | Issue: 4 | Pages: 1148-1160

10.1093/brain/awz025 | PMID 30759182 Get It

AbstractAs more biomarkers for Alzheimer’s disease and age-related brain conditions become available, more sophisticated analytic approaches are needed to take full advantage of the information they convey. Most work has been done using categorical approaches but the joint relationships of tau PET, amyloid PET and cortical thickness in their continuous distributions to cognition have been under-explored. We evaluated non-demented subjects over age 50 years in the Mayo Clinic Study of Aging, 2037 of whom had undergone 3 T MRI scan, 985 amyloid PET scan with 11C-Pittsburgh compound B (PIB) and MRI, and 577 PIB-PET, 18F-AV1451 flortaucipir PET and MRI. Participants received a nine-test cognitive battery. Three test scores (logical memory delayed recall, visual reproduction delayed recall and auditory verbal learning test delayed recall) were used to generate a memory composite z-score. We used Gradient Boosting Machine models to analyse the relationship between regional cortical thickness, flortaucipir PET signal, PIB-PET signal and memory z-scores. Age, education, sex and number of test exposures were included in the model as covariates. In this population-based study of non-demented subjects, most of the associations between biomarkers and memory z-scores accrued after 70 years of age. Entorhinal cortex exhibited the strongest associations between biomarkers and memory z-scores. Other temporal regions showed similar but attenuated associations, and non-temporal regions had negligible associations between memory z-scores and biomarkers. Entorhinal flortaucipir PET signal, PIB-PET signal and entorhinal cortical thickness were independently and additively associated with declining memory z-scores. In contrast to global PIB-PET signal where only very high amyloid-β levels were associated low memory z-scores, entorhinal flortaucipir PET signal just above background levels was associated with low memory z-scores. The lowest memory z-scores occurred with the confluence of elevated entorhinal flortaucipir PET signal and lower entorhinal cortical thickness.
Optimism, Pessimism, and Migraine: A Cross‐Sectional, Population‐Based Study
Peres, Mário Fernando Prieto , Mercante, Juliane Prieto Peres , Kamei, Helder , Tobo, Patrícia Renovato , Rozen, Todd D. , Levin, Morris , Buse, Dawn C. , Lucchetti, Giancarlo , Rozen, Todd D. , Oliveira, Arão Belitardo

Mayo Clinic

Headache: The Journal of Head and Face Pain | January 19, 2019 | Volume: 59 | Issue: 2 | Pages: 205-214

10.1111/head.13471 | PMID 30659602 Get It

Background Optimism and pessimism are related to several mental health and brain disorders, are significant predictors of physical and psychological health outcomes, and implicated as psychosocial determinants of the pain experience. Despite this promising evidence, limited information is available on optimism and pessimism in headache disorders. Objective To evaluate the influence of optimism and pessimism in meeting criteria for migraine and related disability in a population‐based sample. Methods This is an observational, cross‐sectional study. The sample population was selected through a stratified, multi‐stage area probability sample of households, as used by the last Brazilian Census. A validated questionnaire eliciting data on demographics, headache features, migraine‐related disability, depression (PHQ‐9), anxiety (GAD‐7), optimism, and pessimism (life orientation test – revised) was administered to people with migraine and headache‐free control participants from the general population in São Paulo, Brazil via trained interviewers. Six hundred individuals were contacted. The odds for having migraine/no headache diagnosis were calculated by binary logistic regression, and ordinal regression was performed to check associations between migraine‐related disability and optimism. Results A total of 302 individuals (mean ± SD age: 39.7 ± 12.7; BMI: 26.5 ± 5.9) met inclusion criteria and were included, 140 controls (with no history of headache disorders) and 162 people meeting criteria for migraine (29 with chronic migraine, that is, 15 or more headache days/month). People with migraine were less optimistic and more pessimistic than controls, and endorsed higher levels of anxious and depressive symptoms. Pessimism (OR 95% CI = 1.16 [1.05–1.28], P = .005) and anxiety (OR 95% CI = 1.19 [1.10–1.29], P < .001) were predictors of meeting criteria for migraine, while optimism (β 95% CI = −0.915 [−1.643, −0.188], P = .01) was inversely associated with migraine‐related disability. Conclusions Optimism and pessimism are associated with migraine and migraine‐related disability. These concepts should be further explored in people with migraine with regard to their potential influences on clinical research outcomes and treatments.
Predictive utility of an adapted Marshall head CT classification scheme after traumatic brain injury
Pretz, Christopher R. , Bell, Kathleen , Arciniegas, David B. , Bodien, Yelena G. , Hart, Tessa , Johnson‐Greene, Douglas, Kowalski, Robert G. , Weintraub, Alan, Zafonte, Ross , Brown, Allen W. , Bell, Kathleen , Hammond, Flora M. , Dams-O’Connor, Kristen , Giacino, Joseph T. , Johnson‐Greene, Doug , Walker, William C.

Mayo Clinic

Brain Injury | January 19, 2019 | Volume: 33 | Issue: 5 | Pages: 610-617

10.1080/02699052.2019.1566970 | PMID 30663426 Get It

CGRP ligand and receptor monoclonal antibodies for migraine prevention: Evidence review and clinical implications
Dodick, David W.

Mayo Clinic

Cephalalgia | January 19, 2019 | Volume: 39 | Issue: 3 | Pages: 445-458

10.1177/0333102418821662 | PMID 30661365 Get It

Background: Monoclonal antibodies that target calcitonin gene-related peptide or the canonical calcitonin gene-related peptide receptor have emerged as effective and well tolerated for the preventive treatment of migraine. These large molecules appear ideally suited for migraine prevention. They have an extended biological half-life, are administered either monthly or quarterly either by subcutaneous injection or intravenous infusion, require minimal or no dose-titration and have the potential for a rapid onset of effect compared to conventional oral preventive drugs. There is high selectivity and they target an important mediator in the pathogenesis of migraine. Investigation: Phase II and pivotal phase III studies have all yielded positive results with a favorable adverse event profile. No serious treatment-related adverse outcomes have thus far been reported in controlled or long-term open-label extension studies. This tolerability profile promises to improve adherence and, possibly, long-term outcomes. Conclusions: Calcitonin gene-related peptide monoclonal antibodies are effective and well tolerated for the preventive treatment of migraine. They have distinct advantages over currently available oral preventive drugs. While treatment-related serious adverse events have not been observed in open-label extension studies, long-term outcomes and safety will require broad exposure in heterogeneous patient populations in clinical practice. In addition, their safety in women, especially during pregnancy, will require longitudinal surveillance. Given the overlapping mechanism(s), the effectiveness of existing (triptans) and emerging (calcitonin gene-related peptide receptor antagonists) acute therapies in those using a calcitonin gene-related peptide mAb will require further study.